Panmure Gordon reissued their buy rating on shares of Midatech Pharma PLC (LON:MTPH) in a report issued on Friday morning. Panmure Gordon currently has a GBX 380 ($4.96) target price on the stock.

Midatech Pharma PLC (LON:MTPH) traded up 2.01% during mid-day trading on Friday, hitting GBX 127.00. The company’s stock had a trading volume of 3,522 shares. Midatech Pharma PLC has a 52-week low of GBX 100.51 and a 52-week high of GBX 285.00. The firm’s market cap is GBX 42.60 million. The firm has a 50 day moving average of GBX 145.06 and a 200-day moving average of GBX 141.57.

Midatech Pharma PLC Company Profile

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Stock Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related stocks with our FREE daily email newsletter.